Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs.

Sun H, Piotrowski DW, Orr STM, Warmus JS, Wolford AC, Coffey SB, Futatsugi K, Zhang Y, Vaz ADN.

PLoS One. 2018 Nov 14;13(11):e0206279. doi: 10.1371/journal.pone.0206279. eCollection 2018.

2.

Detection of Central Nervous System Infiltration by Myeloid and Lymphoid Hematologic Neoplasms Using Flow Cytometry Analysis: Diagnostic Accuracy Study.

Bento LC, Correia RP, Alexandre AM, Nosawa ST, Pedro EC, Vaz ADC, Schimidell D, Fernandes GBP, Duarte CAS, Barroso RS, Bacal NS.

Front Med (Lausanne). 2018 May 23;5:70. doi: 10.3389/fmed.2018.00070. eCollection 2018.

3.

Technical advances in flow cytometry-based diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria.

Correia RP, Bento LC, Bortolucci AC, Alexandre AM, Vaz AD, Schimidell D, Pedro EC, Perin FS, Nozawa ST, Mendes CE, Barroso RS, Bacal NS.

Einstein (Sao Paulo). 2016 Jul-Sep;14(3):366-373. doi: 10.1590/S1679-45082016AO3641. English, Portuguese.

4.

A tag-free collisionally induced fragmentation approach to detect drug-adducted proteins by mass spectrometry.

Ballard TE, Dahal UP, Bessire AJ, Schneider RP, Geoghegan KF, Vaz AD.

Rapid Commun Mass Spectrom. 2015 Nov 30;29(22):2175-83. doi: 10.1002/rcm.7375.

PMID:
26467230
5.

A simple litmus test for aldehyde oxidase metabolism of heteroarenes.

O'Hara F, Burns AC, Collins MR, Dalvie D, Ornelas MA, Vaz AD, Fujiwara Y, Baran PS.

J Med Chem. 2014 Feb 27;57(4):1616-20. doi: 10.1021/jm4017976. Epub 2014 Feb 5.

6.

Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.

Miao Z, Nucci G, Amin N, Sharma R, Mascitti V, Tugnait M, Vaz AD, Callegari E, Kalgutkar AS.

Drug Metab Dispos. 2013 Feb;41(2):445-56. doi: 10.1124/dmd.112.049551. Epub 2012 Nov 20.

PMID:
23169609
7.

Molecular etiology of atherogenesis--in vitro induction of lipidosis in macrophages with a new LDL model.

Estronca LM, Silva JC, Sampaio JL, Shevchenko A, Verkade P, Vaz AD, Vaz WL, Vieira OV.

PLoS One. 2012;7(4):e34822. doi: 10.1371/journal.pone.0034822. Epub 2012 Apr 13.

8.

Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.

Sharma R, Strelevitz TJ, Gao H, Clark AJ, Schildknegt K, Obach RS, Ripp SL, Spracklin DK, Tremaine LM, Vaz AD.

Drug Metab Dispos. 2012 Mar;40(3):625-34. doi: 10.1124/dmd.111.042770. Epub 2011 Dec 21.

PMID:
22190693
9.

A rapid and specific derivatization procedure to identify acyl-glucuronides by mass spectrometry.

Vaz AD, Wang WW, Bessire AJ, Sharma R, Hagen AE.

Rapid Commun Mass Spectrom. 2010 Jul 30;24(14):2109-21. doi: 10.1002/rcm.4621.

PMID:
20552710
10.

The use of 18O-exchange and base-catalyzed N-dealkylation with liquid chromatography/tandem mass spectrometry to identify carbinolamide metabolites.

Bessire AJ, Vaz AD, Walker GS, Wang WW, Sharma R.

Rapid Commun Mass Spectrom. 2010 Jul 30;24(14):2151-61. doi: 10.1002/rcm.4595.

PMID:
20552706
11.

Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools.

Sawant AD, Miller EL, Duignan DB, Brodfuehrer J, Winter SM, Nelson FR, Kamel A, Obach RS, Vaz AD.

Xenobiotica. 2010 Jul;40(7):476-84. doi: 10.3109/00498254.2010.481057.

PMID:
20429841
12.

Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.

Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.

J Med Chem. 2009 Dec 10;52(23):7446-57. doi: 10.1021/jm900729s.

PMID:
19775168
13.

Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans.

Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, Obach RS.

Drug Metab Dispos. 2008 Nov;36(11):2185-98. doi: 10.1124/dmd.108.023176. Epub 2008 Aug 11.

PMID:
18694908
14.

Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans.

Shaffer CL, Gunduz M, Vaz AD, Venkatakrishnan K, Burstein AH.

Drug Metab Dispos. 2008 Apr;36(4):655-62. doi: 10.1124/dmd.107.019760. Epub 2008 Jan 7.

PMID:
18180269
15.

Absorption, distribution, metabolism, and excretion of dirlotapide in the dog.

Merritt DA, Bessire AJ, Vaz AD, Sams JP, Lynch MP.

J Vet Pharmacol Ther. 2007 Aug;30 Suppl 1:17-23.

PMID:
17567511
16.

Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4.

Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE.

Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18.

PMID:
15978881
17.

MT FdR: a ferredoxin reductase from M. tuberculosis that couples to MT CYP51.

Zanno A, Kwiatkowski N, Vaz AD, Guardiola-Diaz HM.

Biochim Biophys Acta. 2005 Apr-May;1707(2-3):157-69. Epub 2004 Dec 15.

18.

Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4.

Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, Hop CE.

Drug Metab Dispos. 2005 Feb;33(2):243-53. Epub 2004 Nov 2. Erratum in: Drug Metab Dispos. 2005 May;33(5):696.

PMID:
15523046
20.

In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.

Cohen LH, Remley MJ, Raunig D, Vaz AD.

Drug Metab Dispos. 2003 Aug;31(8):1005-15.

PMID:
12867489
21.
22.

Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis.

Guardiola-Diaz HM, Foster LA, Mushrush D, Vaz AD.

Biochem Pharmacol. 2001 Jun 15;61(12):1463-70.

PMID:
11377375
23.

Discrete species of activated oxygen yield different cytochrome P450 heme adducts from aldehydes.

Kuo CL, Raner GM, Vaz AD, Coon MJ.

Biochemistry. 1999 Aug 10;38(32):10511-8.

PMID:
10441147
24.

Multiple activated oxygen species in P450 catalysis: contributions To specificity in drug metabolism.

Coon MJ, Vaz AD, McGinnity DF, Peng HM.

Drug Metab Dispos. 1998 Dec;26(12):1190-3. Review.

PMID:
9860926
25.
26.

Significance of glycine 478 in the metabolism of N-benzyl-1-aminobenzotriazole to reactive intermediates by cytochrome P450 2B1.

Kent UM, Hanna IH, Szklarz GD, Vaz AD, Halpert JR, Bend JR, Hollenberg PF.

Biochemistry. 1997 Sep 30;36(39):11707-16.

PMID:
9305960
28.
29.
30.

Adrenal proteins bound by a reactive intermediate of mitotane.

Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD, Wotring LL.

Cancer Chemother Pharmacol. 1997;39(6):537-40.

31.

Evidence for a role of a perferryl-oxygen complex, FeO3+, in the N-oxygenation of amines by cytochrome P450 enzymes.

Guengerich FP, Vaz AD, Raner GN, Pernecky SJ, Coon MJ.

Mol Pharmacol. 1997 Jan;51(1):147-51.

PMID:
9016357
32.

Metabolic activation of 2,6-dichlorobenzonitrile, an olfactory-specific toxicant, by rat, rabbit, and human cytochromes P450.

Ding X, Spink DC, Bhama JK, Sheng JJ, Vaz AD, Coon MJ.

Mol Pharmacol. 1996 Jun;49(6):1113-21.

PMID:
8649351
34.

Cytochrome P450 2: peroxidative reactions of diversozymes.

Coon MJ, Vaz AD, Bestervelt LL.

FASEB J. 1996 Mar;10(4):428-34. Review.

PMID:
8647341
37.

Oxidative cleavage of esters and amides to carbonyl products by cytochrome P450.

Peng HM, Raner GM, Vaz AD, Coon MJ.

Arch Biochem Biophys. 1995 Apr 20;318(2):333-9.

PMID:
7733661
38.

Old Yellow enzyme: aromatization of cyclic enones and the mechanism of a novel dismutation reaction.

Vaz AD, Chakraborty S, Massey V.

Biochemistry. 1995 Apr 4;34(13):4246-56.

PMID:
7703238
39.
40.
41.
42.

Cytochrome P450: progress and predictions.

Coon MJ, Ding XX, Pernecky SJ, Vaz AD.

FASEB J. 1992 Jan 6;6(2):669-73. Review.

PMID:
1537454
43.

Substituted pyridines: nonsteroidal inhibitors of human placental aromatase cytochrome P-450.

Vaz AD, Coon MJ, Peegel H, Menon KM.

Drug Metab Dispos. 1992 Jan-Feb;20(1):108-12.

PMID:
1346984
44.
45.
46.

Reductive cleavage of hydroperoxides by cytochrome P-450.

Vaz AD, Coon MJ.

Methods Enzymol. 1990;186:278-82. No abstract available.

PMID:
2233300
47.

Affinity labeling of bovine opsin by trans-retinoyl chloromethane.

Vaz AD, Schoellmann G.

Biochem Biophys Res Commun. 1989 Apr 28;160(2):942-7.

PMID:
2524196
48.
49.

Radical intermediates in the catalytic cycles of cytochrome P-450.

Vaz AD, Roberts ES, Coon MJ.

Basic Life Sci. 1988;49:501-7.

PMID:
2854994
50.

Microsomal cholesterol epoxide hydrolase activity in 2-acetylaminofluorene-induced rat liver hyperplastic nodules.

Palakodety RB, Vaz AD, Griffin MJ.

Biochem Pharmacol. 1987 Jul 15;36(14):2424-7. No abstract available.

PMID:
3606651

Supplemental Content

Support Center